Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.

– Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.

DURHAM, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today provided a commercial update highlighting increasing momentum in the launch of Symvess, its FDA-approved acellular tissue engineered vessel (ATEV) for vascular trauma. Symvess is seeing accelerating hospital adoption, increasing clinical utilization, and growing enthusiasm among leading vascular surgeons and healthcare providers.

"Our commercial execution is generating strong momentum across the United States and validating the significant unmet need for an off-the-shelf bioengineered vascular conduit," said Jim Mercadante, Chief Commercial Officer of Humacyte. "The increasing rate of new hospital adoption, growing physician engagement, and expanding utilization highlight the power of the new commercial strategy we set in place in Q2 2026. More surgeons are learning about our product, driving increased hospital network engagement and expanding contracts being put in place, translating into strong revenue growth. We believe the acceleration we have seen throughout the third quarter positions us for substantial growth throughout the remainder of 2026."

Third Quarter 2026 Commercial Highlights

• Hospital adoption expanded significantly, and the number of hospitals that have ordered Symvess increased by 44% during the third quarter, from 34 hospitals at the end of the second quarter to 49 hospitals as of September 30, 2026, showcasing the potential to surpass Humacyte’s goal of adding 20 new hospitals by year-end.
• Commercial sales accelerated, as new hospital ordering activity increased sequentially each month of the third quarter.
• Symvess is generating substantial interest among vascular surgeons and healthcare providers. Multiple surgeons who have utilized Symvess in clinical practice have submitted patient case studies for presentations, highlighting real-world experience and growing physician engagement.